智通财经APP讯，轩竹生物-B(02575)公布，于 2025年 11月 17日，公司已向中国证监会提交备案申请，内容有关建议实施H股全流通，以按一对一基准将合共357,245,794股未上市股份转换为H股。待完成所有备案规定(包括向中国证监会备案)并获得所有相关批准(包括联交所批准转换及上市)并遵守所有适用法律、法规及规则后，357,245,794股未上市股份将转换为357,245,794股H股，并将于联交所上市及买卖。
智通财经APP讯，轩竹生物-B(02575)公布，于 2025年 11月 17日，公司已向中国证监会提交备案申请，内容有关建议实施H股全流通，以按一对一基准将合共357,245,794股未上市股份转换为H股。待完成所有备案规定(包括向中国证监会备案)并获得所有相关批准(包括联交所批准转换及上市)并遵守所有适用法律、法规及规则后，357,245,794股未上市股份将转换为357,245,794股H股，并将于联交所上市及买卖。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.